A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study

  title={A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study},
  author={Atsushi Yaguchi and Kenji Akahane and Kumi Tsuchioka and Saori Yonekubo and Shota Yamamoto and Yasuaki Tamai and Satoshi Tatemichi and Hiroo Takeda},
  journal={BMC Nephrology},
BackgroundApproximately 30% of patients on dialysis received combination therapy for their phosphate binder prescription; however, few studies for combined effects of phosphate binders are reported. For the purpose of evaluating the efficacy of combination therapy, we compared the efficacy of sucroferric oxyhydroxide (PA21) combined with calcium carbonate with that of lanthanum carbonate hydrate, sevelamer hydrochloride, and ferric citrate hydrate combined with calcium carbonate.MethodsFor in… Expand
Necessity of examining the practical efficacy of phosphate binders
  • M. Tanemoto, Takahide Kimura, Seiki Yamada
  • Medicine
  • Clinical and Experimental Nephrology
  • 2021
The findings of this retrospective analysis with a small sample size at a single center were limited by possible selection bias and the PBE of PBs in clinical practice should be examined in future studies that are larger in scale and examine the influence of concomitant therapy. Expand


Comparison of Phosphate Binding Capacities of PA21, A Novel Phosphate Binder, with those of other Phosphate Binders in vitro and in vivo.
In vitro studies revealed that PA21 and sevelamer hydrochloride adsorbed phosphate better at all tested pH levels than lanthanum carbonate hydrate, calcium carbonate, and ferric citratehydrate, and PA21 showed the most potent phosphate binding capacity among the tested compounds. Expand
Comparative analysis of the phosphate-binding effects of sucroferric oxyhydroxide, ferric citrate, and lanthanum carbonate
Sucroferric oxyhydroxide possesses better phosphate-binding efficacies than ferric citrate and lanthanum carbonate, and showed a strong iron-cumulative effect. Expand
Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients
Combined administration of sucroferric oxyhydroxide and calcium carbonate at low doses was effective in maintaining serum phosphorus concentrations within the target range, and patients’ gastrointestinal status improved. Expand
Effect of famotidine and lansoprazole on serum phosphorus levels in hemodialysis patients on calcium carbonate therapy.
Not only administration of 20 mg/ day of famotidine, but also 10 mg/day of this drug (the recommended dose for hemodialysis patients) caused a significant increase of serum phosphate in patients taking calcium carbonate. Expand
Determination of calcium salt solubility with changes in pH and PCO2, simulating varying gastrointestinal environments
Calculated profiles using in‐vivo calcium and bicarbonate concentrations demonstrate that large calcium doses may not further increase intestinal calcium absorption once the calcium carbonate solubility product has been reached. Expand
Does Concomitant Administration of Sevelamer and Calcium Carbonate Modify the Control of Phosphatemia?
  • G. Ouellet, H. Cardinal, M. Mailhot, L. Ste‐Marie, L. Roy
  • Medicine
  • Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • 2010
The results show that simultaneous administration of calcium carbonate and sevelamer does not decrease phosphate‐binding capacity and patients can choose to take their phosphate binders concomitantly or at separate meals, according to their preference. Expand
The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro.
It is demonstrated that PA21 has potent phosphate binding capacity and low iron release over a physiologically relevant pH range in the GI tract, which indicate PA21 could be an effective alternative phosphate binder for CKD patients. Expand
An Update on Phosphate Binders: A Dietitian's Perspective.
  • Lisa Gutekunst
  • Medicine
  • Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation
  • 2016
A comprehensive review, geared to the renal dietitian, of the most common binder categories and two novel approaches to serum PO4 management in chronic kidney disease patients receiving dialysis are reviewed. Expand
Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles
This paper reviews the use of phosphate binders in patients with CKD on dialysis, with a focus on safety and tolerability, and a new resin-based phosphate binder, colestilan, is discussed. Expand
Influence of proton pump inhibitors and histamine H2 receptor antagonists on serum phosphorus level control by calcium carbonate in patients undergoing hemodialysis: a retrospective medical chart review
Concomitant use of ARs with CaC may attenuate the hypophosphatemic effect of CaC in patients undergoing chronic hemodialysis, and it may be prudent to choose a phosphate binder other than CaC. Expand